Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data-Reference-Cited by-同舟云学术

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data

Published:2022-12-08 Issue:2 Volume:10 Page:329-341
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Yoo Wan-Hee,Kang Young Mo,Kim Dong Wook,Kang Eun Ha,Lee Yeon-Ah,Suh Chang-Hee,Sung Yoon-Kyoung,Lee Sang-Hoon,Gu Dong-Ha,Lee Jiwon,Choe Jung-Yoon^ORCID

Funder

Samsung Bioepis

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-022-00515-z.pdf

Reference26 articles.

1. Cobo-Ibáñez T, Martín-Mola E. Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. Expert Opin Pharmacother. 2007;8(9):1373–97.

2. Guillot X, et al. Etanercept for treating axial spondyloarthritis. Expert Opin Biol Ther. 2017;17(9):1173–81.

3. Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173–9.

4. Emery P, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51–7.

5. Emery P, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology. 2017;56(12):2093–101.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System;RMD Open;2024-03

2. Etanercept;Reactions Weekly;2023-11-04

3. Current and emerging prospects in the psoriatic treatment;International Immunopharmacology;2023-07